Manuscript on KBR method to be published in American Journal of Cardiology

Dec 9 2009

VentriPoint Diagnostics Ltd. ("VentriPoint" or the "Corporation") (TSX VENTURE:VPT) is pleased to announce that the manuscript entitled, "Accuracy of Knowledge Based Reconstruction (KBR) for Measurement of Right Ventricular Volume and Function in Patients with Tetralogy of Fallot" has been accepted for publication in the American Journal of Cardiology. The study will be published in the journal's April, 2010 issue.

This study demonstrated the accuracy and reproducibility of the KBR method which enables physicians to monitor their patients' hearts from ultrasound or magnetic resonance images. The results of the study were presented at the Scientific Sessions of the American Heart Association in November, 2008 by the lead author, Dr. Florence Sheehan, a cardiologist and professor at the University of Washington. She led a multinational team of investigators in collecting and analyzing patient data for the study.

The KBR method was successfully applied for patients with the most common type of congenital heart disease (CHD) causing a "blue baby" at birth. Studies are in progress at VentriPoint to validate KBR for the other types of CHD. The investigative team has enlarged to now include sites in Canada, the UK, the Netherlands, and Switzerland in addition to the U.S., indicating the intense clinical need everywhere for VentriPoint's service.

"The acceptance of this manuscript by such an esteemed authority as the American Journal of Cardiology represents a validation of our efforts to introduce a much needed tool for monitoring right ventricular volume and function from 2D Ultrasounds images," stated Joe Ashley, President & CEO of the Corporation. "We continue to pursue the European and U.S. regulatory authority and the requisite capital to commercialize our exceptionally accurate system to health professionals as a tool for their diagnosis and treatment of cardiovascular disease. Rapid and accurate right ventricle measurements is essential for patient assessment."

There are greater than 1 million American adults and 800,000 children with CHD, according to the American Heart Association and the Adult Congenital Heart Association. With 36,000 CHD births every year, the number of CHD patients requiring serial RV monitoring is rising due to their longer survival as a result of extremely successful diagnostic and treatment strategies developed and employed over the past 40 years. VentriPoint also plans to extend its service to patients with other types of lung and heart diseases, bringing the total estimated market for the VentriPoint Medical System to exceed $5 Billion worldwide.